Phase 2
N=51
Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Bottom Line
View on ClinicalTrials.gov: NCT00635700 ↗Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Oct 2016
Primary outcome: Primary: Conversion to Psychosis — 1; 2 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- ziprasidone (Drug); placebo (Drug)
- Age
- Pediatric, Adult · 16+ yrs
- Sex
- All
- Sponsor
- Yale University
- Primary completion
- Nov 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Conversion to Psychosis |
1; 2 | — |
| SECONDARY Change in Scale of Psychosis-risk Symptoms Total Score |
-0.271; 0 | — |
Summary
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
Eligibility Criteria
Inclusion Criteria
- Structured Interview for Psychosis-risk Syndromes criteria for Clinical High Risk for Psychosis
- clinically referred
Exclusion Criteria
- prolonged corrected QT interval
- history of syncope
Data sourced from ClinicalTrials.gov (NCT00635700). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.